IPOs on Nasdaq, backed by Eli Lilly, focusing on Treg science for autoimmune disorders. Pipeline includes TRB-061 and a CD30 agonist for IBD.
WHO releases preeclampsia roadmap; Comanche, DiaMedica, Avilar & ProFound developing treatments; Eli Lilly exploring the ...
PhRMA says FDA will get money it can spend only on hiring and keeping staff, to restore reviewer levels after the HHS layoffs ...
Biohaven licenses pan-IgG degraders to Ono for $80M; UK pulls Ixchiq; ADC raises $86.6M; BMS Zenbexus Phase 3 win; Pfizer ...
Petrelintide reduced patients’ average body weight by up to 9.2%, compared to 2.0% among those who received placebo.
Roche partners with Hangzhou-based Defand Therapeutics in a ~$1B deal, under $10M upfront, to develop molecular glue ...
Grindr acquires Freddie's parent for $250M to expand into HIV prevention (PrEP). The company will combine that with ED drugs and GLP-1s under new Grindr Health brand.
General Medicine raises a $120M Series B led by a16z, betting its 2,900-product catalog can serve AI shopping agents as well as people.
Chan Zuckerberg Biohub launches $1.8B Virtual Biology Initiative with Meta, Google DeepMind, Isomorphic Labs, DOE, and NIH to ...
Plus news about Denali, Nuvectis Pharma, Graph Therapeutics, GondolaBio and the Novo Nordisk Foundation. 🔗 Eli Lilly’s alliance with BioArctic: The Indianapolis drug giant will ...
Ultragenyx sells a rare pediatric disease PRV for $210M, one of 2026's priciest voucher deals, and plans to monetize a second ...
The World Health Organization on Wednesday recommended against GLP-1 drugs for children with obesity who are under 10 and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results